Sprint Bioscience AB (publ)

Sprint Bioscience AB (publ) is a pharmaceutical company focused on developing therapies for cancer and metabolic disorders. Its operations span internationally, with a presence in Sweden, across Europe, the United States, and Asia. The firm is currently advancing key drug candidates, including VPS34, which is being developed to treat various forms of cancer, and PETRA01, another prospective cancer treatment. Additionally, the company dedicates research efforts to understanding and treating conditions such as tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was established in 2009 and maintains its headquarters in Huddinge, Sweden.